{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:39:22Z","timestamp":1777264762356,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007558","name":"Rutgers Cancer Institute of New Jersey","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007558","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA072720"],"award-info":[{"award-number":["P30CA072720"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA180984"],"award-info":[{"award-number":["T32CA180984"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.urolonc.2025.01.004","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T11:35:21Z","timestamp":1738323321000},"page":"269.e7-269.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rethinking the definition of stage III disease in adrenocortical carcinoma: Assessing the impact of clinical lymph node positive disease"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9376-7961","authenticated-orcid":false,"given":"Benjamin J.","family":"Lichtbroun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Chua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Pfail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Passarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiren V.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sammy","family":"Elsamra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vignesh T.","family":"Packiam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Golombos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L.","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saum","family":"Ghodoussipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnav","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.01.004_bib0001","first-page":"14","article-title":"Adrenal Gland Tumor: sstatistics","year":"2023","journal-title":"CancerNET"},{"key":"10.1016\/j.urolonc.2025.01.004_bib0002","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fcell.2015.00045","article-title":"Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment","volume":"3","author":"Libe","year":"2015","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.urolonc.2025.01.004_bib0003","first-page":"8990","article-title":"Adrenalectomy for benign and malignant disease: utilization and outcomes by surgeon specialty and surgical approach from 2003 to 2013","volume":"24","author":"Faiena","year":"2017","journal-title":"Can J Urol"},{"key":"10.1016\/j.urolonc.2025.01.004_bib0004","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"Libe","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2025.01.004_bib0005","first-page":"93","article-title":"The Eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2025.01.004_bib0006","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.surg.2018.04.068","article-title":"Longitudinal patterns of recurrence in patients with adrenocortical carcinoma","volume":"165","author":"Glenn","year":"2019","journal-title":"Surgery"},{"key":"10.1016\/j.urolonc.2025.01.004_bib0007","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/cancers14020291","article-title":"Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma-a systematic review and meta-analysis","volume":"14","author":"Hendricks","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2025.01.004_bib0008","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.24030","article-title":"Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification","volume":"115","author":"Fassnacht","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.01.004_bib0009","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","article-title":"The National Cancer Data Base: a powerful initiative to improve cancer care in the United States","volume":"15","author":"Bilimoria","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.urolonc.2025.01.004_bib0010","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors","volume":"113","author":"Bilimoria","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.01.004_bib0011","first-page":"70","article-title":"Prognosis of stage III adrenocortical carcinoma after radical resection: a French retrospective multicentric study from the COMETE Network","author":"Do Cao SL","year":"2011","journal-title":"Eur Congress Endocrinol"},{"key":"10.1016\/j.urolonc.2025.01.004_bib0012","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s00268-020-05801-x","article-title":"Positive lymph nodes in adrenocortical carcinoma: what does it mean?","volume":"45","author":"Sada","year":"2021","journal-title":"World J Surg"},{"key":"10.1016\/j.urolonc.2025.01.004_bib0013","unstructured":"Adrenal Gland Tumors. National Comprehensive Cancer Network Clinical Practice Guidelines in oncology 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf. Accessed January 28, 2024."},{"key":"10.1016\/j.urolonc.2025.01.004_bib0014","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/jamasurg.2022.3544","article-title":"American Association of Endocrine Surgeons Guidelines for Adrenalectomy: executive Summary","volume":"157","author":"Yip","year":"2022","journal-title":"JAMA Surg"},{"key":"10.1016\/j.urolonc.2025.01.004_bib0015","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1245\/s10434-016-5536-1","article-title":"Lymphadenectomy for adrenocortical carcinoma: is there a therapeutic benefit?","volume":"23","author":"Gerry","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.urolonc.2025.01.004_bib0016","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/SLA.0b013e3182367ac3","article-title":"Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma","volume":"255","author":"Reibetanz","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.urolonc.2025.01.004_bib0017","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S2213-8587(23)00193-6","article-title":"Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study","volume":"11","author":"Terzolo","year":"2023","journal-title":"Lancet Diabet Endocrinol"},{"key":"10.1016\/j.urolonc.2025.01.004_bib0018","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jamcollsurg.2015.12.013","article-title":"Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US Adrenocortical Carcinoma Group","volume":"222","author":"Postlewait","year":"2016","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.urolonc.2025.01.004_bib0019","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","article-title":"Using the National Cancer Database for Outcomes Research: a review","volume":"3","author":"Boffa","year":"2017","journal-title":"JAMA Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T03:56:59Z","timestamp":1777262219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925000043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1078143925000043"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.01.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rethinking the definition of stage III disease in adrenocortical carcinoma: Assessing the impact of clinical lymph node positive disease","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}